Complete Guide to Liver Disease: Cirrhosis, Portal Hypertension, and Scoring Systems

The liver is among the most metabolically complex organs in the human body — a chemical factory, filtration system, and nutrient depot all in one. It is also remarkably resilient. Because it has an enormous functional reserve and cannot perceive pain in its own parenchyma, liver disease progresses silently for years or even decades before causing noticeable symptoms. By the time most patients are diagnosed with cirrhosis, irreversible architectural damage has already occurred.

This guide covers the full spectrum of liver disease: anatomy and function, the common causes of chronic liver injury, how fibrosis progresses to cirrhosis, the non-invasive tools used to detect it, the catastrophic complications of portal hypertension, and the validated scoring systems — Child-Pugh, MELD, FIB-4, and APRI — that clinicians use every day to guide management and transplant decisions.

This guide is for educational purposes only and does not substitute for professional medical advice. Liver disease should be evaluated and managed by a qualified gastroenterologist or hepatologist.

---

Liver Anatomy and Function

The liver is the largest solid organ in the body, weighing approximately 1.2–1.5 kg in adults and sitting beneath the right hemidiaphragm in the right upper quadrant. It receives a dual blood supply: approximately 75% of hepatic blood flow arrives via the portal vein (carrying nutrient-rich blood from the intestines, spleen, and pancreas), and 25% from the hepatic artery (carrying oxygenated blood from the aorta). Venous drainage exits through the hepatic veins into the inferior vena cava.

The functional unit of the liver is the hepatic lobule — a hexagonal structure with a central vein surrounded by six portal triads (each containing a portal vein branch, hepatic artery branch, and bile ductule). The acinus model, based on oxygen delivery, divides the lobule into three zones:

• Zone 1 (periportal): Highest oxygen and nutrient delivery; most resistant to ischemic injury; site of oxidative metabolism
• Zone 2 (midzonal): Intermediate characteristics
• Zone 3 (centrilobular): Lowest oxygen delivery; most susceptible to ischemic and toxic injury (including alcohol and acetaminophen)

Core Liver Functions

Understanding liver function helps explain why cirrhosis produces its specific constellation of complications:

1. Detoxification and drug metabolism The liver clears ammonia (converting it to urea for renal excretion), metabolizes most orally administered drugs (first-pass metabolism), inactivates hormones, and conjugates bilirubin for biliary excretion. When these functions fail, ammonia accumulates (hepatic encephalopathy), drug toxicity increases, and jaundice develops.

2. Protein synthesis Hepatocytes synthesize:

• Albumin (the main plasma oncotic protein; hypoalbuminemia causes edema and ascites)
• Clotting factors I (fibrinogen), II (prothrombin), V, VII, IX, X (all vitamin K-dependent factors except V)
• Complement proteins, transport proteins (transferrin, ceruloplasmin), and insulin-like growth factor-1

When synthetic function fails, patients develop coagulopathy (reflected by elevated INR) and hypoalbuminemia, two of the five variables in the Child-Pugh score.

3. Bile production The liver produces 600–1,000 mL of bile daily, essential for emulsifying dietary fats and absorbing fat-soluble vitamins (A, D, E, K). Cholestasis — impaired bile flow — leads to fat malabsorption, vitamin K deficiency (worsening coagulopathy), and pruritus.

4. Carbohydrate and lipid metabolism The liver stores approximately 100 g of glycogen, maintains fasting blood glucose through glycogenolysis and gluconeogenesis, and is the primary site of VLDL synthesis, cholesterol production, and fatty acid oxidation.

5. Immune function Kupffer cells (resident hepatic macrophages) clear bacteria, endotoxins, and foreign particles arriving from the portal circulation. Loss of Kupffer cell function in cirrhosis increases susceptibility to bacterial infections, including spontaneous bacterial peritonitis.

Why Early Liver Disease Is "Silent"

The liver has a functional reserve of 70–80%, meaning symptoms typically do not appear until more than 80% of hepatic parenchyma is destroyed or dysfunctional. Additionally, the liver has no pain receptors within its parenchyma (only its capsule can sense pain). Early liver disease produces nonspecific symptoms at best — fatigue, mild right upper quadrant discomfort, or subtle metabolic changes — that are easily attributed to other causes.

This explains why viral hepatitis can silently progress to cirrhosis over 20–30 years, why NAFLD is often discovered incidentally on abdominal imaging, and why routine screening of at-risk populations is so important.

---

Causes of Chronic Liver Disease

Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH

Non-alcoholic fatty liver disease is now the most common liver condition in the world, affecting an estimated 25% of the global population — approximately 2 billion individuals. Prevalence exceeds 40% in patients with type 2 diabetes or metabolic syndrome. NAFLD is now the leading cause of cirrhosis in developed countries and the second most common indication for liver transplantation in the United States after hepatitis C.

The spectrum ranges from:

• Simple hepatic steatosis (fat accumulation without significant inflammation): low risk of progression; <5% develop cirrhosis over 10–15 years
• Non-alcoholic steatohepatitis (NASH): fat plus hepatocellular inflammation and ballooning degeneration; 15–25% progress to cirrhosis over 10–20 years

Risk factors: obesity (BMI >30), type 2 diabetes, insulin resistance, dyslipidemia, hypertension, sleep apnea, hypothyroidism, PCOS

In 2023, the field adopted new nomenclature: metabolic dysfunction-associated steatotic liver disease (MASLD) replaces NAFLD, and metabolic dysfunction-associated steatohepatitis (MASH) replaces NASH, to better reflect the metabolic underpinnings of the condition.

Alcoholic Liver Disease (ALD)

Chronic alcohol consumption is the second most common cause of cirrhosis worldwide. Risk of significant liver damage increases with consumption >2–3 standard drinks per day in women or >3–4 drinks per day in men, though individual susceptibility varies substantially based on genetics (PNPLA3, TM6SF2 variants), sex (women develop ALD at lower alcohol doses), nutritional status, and co-existing liver disease.

The spectrum of ALD includes:

• Alcoholic fatty liver (steatosis): Reversible with abstinence; present in ~90% of heavy drinkers
• Alcoholic hepatitis: Acute inflammatory injury; can range from mild (incidentally discovered) to severe (Maddrey discriminant function >32, MELD >20); severe alcoholic hepatitis carries 28-day mortality of 30–50%
• Alcoholic cirrhosis: Irreversible in most cases; accounts for approximately 48% of all cirrhosis-related deaths in the US

Viral Hepatitis

Hepatitis B (HBV): Approximately 296 million people are chronically infected with HBV worldwide, predominantly in sub-Saharan Africa and Asia. Chronic HBV increases the risk of cirrhosis and hepatocellular carcinoma (HCC) — HBV accounts for 50–55% of HCC cases globally. Vertical transmission (mother to child) is the dominant route in high-prevalence regions. Effective vaccines have existed since 1982; universal infant vaccination is the primary prevention strategy. Oral antiviral therapy (tenofovir, entecavir) suppresses viral replication and reduces cirrhosis progression.

Hepatitis C (HCV): Approximately 58 million people are chronically infected with HCV worldwide. HCV is the leading cause of liver transplantation in the United States. The advent of direct-acting antiviral (DAA) therapy has transformed HCV management: 8–12 week oral regimens achieve sustained virologic response (cure) rates exceeding 95–99% across all genotypes, with minimal side effects. Despite cure rates, patients with established cirrhosis remain at elevated risk for HCC and decompensation and require ongoing surveillance.

Autoimmune Liver Diseases

• Autoimmune hepatitis (AIH): Immune-mediated hepatocellular injury; affects predominantly women; characterized by elevated IgG, positive ANA and/or anti-smooth muscle antibody (ASMA); responds to immunosuppression (prednisone + azathioprine)
• Primary biliary cholangitis (PBC): Immune-mediated destruction of intrahepatic bile ducts; elevated ALP, positive anti-mitochondrial antibody (AMA); treated with ursodeoxycholic acid (UDCA) and obeticholic acid
• Primary sclerosing cholangitis (PSC): Multifocal inflammation and fibrosis of both intra- and extrahepatic bile ducts; strongly associated with inflammatory bowel disease (especially ulcerative colitis); no effective medical therapy; often requires liver transplantation

Genetic and Metabolic Liver Diseases

• Wilson's disease: Autosomal recessive disorder of copper metabolism (ATP7B gene mutation); copper accumulates in liver, brain, eyes (Kayser-Fleischer rings); presents in young adults; treated with chelation (D-penicillamine, trientine) or zinc
• Hereditary hemochromatosis: Autosomal recessive iron overload disorder (HFE gene); excessive iron deposition in liver (cirrhosis), heart (cardiomyopathy), pancreas (diabetes), joints, and skin; treated with phlebotomy
• Alpha-1 antitrypsin deficiency: Abnormal protein accumulates in hepatocytes; may cause neonatal hepatitis, childhood liver disease, or adult cirrhosis; lung disease (emphysema) also common

---

Fibrosis Progression: From Inflammation to Cirrhosis

Regardless of cause, chronic liver injury follows a common pathologic pathway: sustained hepatocyte damage activates hepatic stellate cells (HSCs), which transform into myofibroblasts and deposit collagen, progressively replacing functional liver tissue with scar tissue. This process — fibrosis — is staged histologically using the METAVIR system:

| METAVIR Stage | Description | Clinical Relevance | |---|---|---| | F0 | No fibrosis | Normal liver architecture | | F1 | Portal fibrosis without septa | Early fibrosis; no significant complications | | F2 | Portal fibrosis with few septa | Significant fibrosis; FIB-4 and APRI begin to flag | | F3 | Bridging fibrosis (many septa) | Advanced fibrosis; portal hypertension may begin | | F4 | Cirrhosis | Irreversible scarring; nodular regeneration; full complication spectrum |

Reversibility

One of the most important paradigm shifts in hepatology over the past two decades is the recognition that early fibrosis (F1–F2) can be reversed with effective treatment of the underlying cause. Patients who achieve viral cure from HCV with DAA therapy, who abstain from alcohol, or who lose significant weight with NAFLD/MASH can experience meaningful fibrosis regression, sometimes from F3 back to F1–F2.

Established cirrhosis (F4) was long considered irreversible, but emerging evidence suggests that even some patients with compensated cirrhosis can experience partial regression with effective disease control. Complete normalization of hepatic architecture is generally not achievable once bridging fibrosis is established.

---

Non-Invasive Fibrosis Assessment

Liver biopsy has been the gold standard for fibrosis staging, but it is invasive, carries a small but real risk of complications (bleeding, pain, rare mortality), is subject to sampling error (the needle samples <1/50,000 of total liver volume), and has significant inter-observer variability. For these reasons, non-invasive fibrosis tests have become increasingly central to clinical practice.

FIB-4 Score

The FIB-4 (Fibrosis-4) index is one of the most widely validated and guideline-endorsed non-invasive fibrosis tests. It uses four simple laboratory values and age:

Formula: FIB-4 = (Age × AST) ÷ (Platelets × √ALT)

Where:

• Age is in years
• AST is in U/L
• Platelets are in 10⁹/L (×10³/µL)
• ALT is in U/L

Interpretation:

| FIB-4 Score | Interpretation | Recommended Action | |---|---|---| | <1.30 | Low risk of advanced fibrosis | Routine monitoring; reassess in 1–2 years | | 1.30–2.67 | Indeterminate zone | Additional testing (elastography, liver biopsy) | | >2.67 | High risk of advanced fibrosis (F3–F4) | Hepatology referral; consider biopsy |

The AASLD and EASL 2024 guidelines for MASLD recommend FIB-4 as the first-line non-invasive fibrosis test in all patients with suspected NAFLD/MASH seen in non-specialist settings. Calculate your FIB-4 score using the FIB-4 Calculator on this site.

Limitations: FIB-4 is less reliable in patients under 35 years (low specificity — too many false positives) and over 65 years (low specificity — high false positive rate due to age in the numerator). Acute hepatitis, rapid platelet fluctuations, and conditions affecting ALT can also reduce accuracy.

APRI Score (AST-to-Platelet Ratio Index)

The APRI score uses only two variables — AST and platelet count — making it the simplest non-invasive fibrosis test:

Formula: APRI = (AST ÷ Upper Limit of Normal for AST) × 100 ÷ Platelet Count (10⁹/L)

Interpretation:

| APRI Score | Interpretation | |---|---| | <0.5 | Low probability of significant fibrosis (≥F2) | | 0.5–1.5 | Indeterminate | | >1.5 | High probability of significant fibrosis (≥F2) | | >2.0 | Cirrhosis more likely |

APRI has been particularly well validated in HCV-related fibrosis and remains the WHO's recommended non-invasive test in resource-limited settings due to its simplicity. Use the APRI Score Calculator on this site to calculate your score.

Liver Elastography

Non-invasive measurement of liver stiffness using ultrasound- or MRI-based elastography has become the most accurate non-invasive fibrosis assessment available:

• Transient elastography (FibroScan): Measures liver stiffness in kPa; values <7 kPa indicate no significant fibrosis; values >12–14 kPa indicate cirrhosis (thresholds vary by etiology)
• Acoustic radiation force impulse (ARFI) / shear wave elastography: Integrated into standard ultrasound machines; similar diagnostic performance to FibroScan
• MR elastography (MRE): Most accurate non-invasive fibrosis test; excellent for morbidly obese patients where FibroScan has high failure rates

---

Cirrhosis: Compensated vs. Decompensated

Cirrhosis represents the irreversible end-stage of fibrosis, characterized histologically by diffuse nodular regeneration surrounded by fibrous septa, replacing normal hepatic architecture. Functionally, cirrhosis impairs all liver functions and creates pathological resistance to portal blood flow.

Compensated Cirrhosis

Patients with compensated cirrhosis have sufficient residual hepatic function to maintain most metabolic and synthetic activities. They may have:

• Mildly elevated transaminases or bilirubin
• Thrombocytopenia (from hypersplenism due to portal hypertension)
• Subtle coagulopathy (mildly elevated INR)
• Esophageal varices on endoscopy (without bleeding)

The 5-year survival for compensated cirrhosis is 80–90%, and many patients remain in compensated state for years to decades.

Decompensated Cirrhosis

Decompensation is defined by the development of one or more major complications that reflect loss of hepatic functional reserve and/or significant portal hypertension:

1. Ascites (most common first decompensation event, occurring in ~60% of compensated cirrhosis patients within 10 years)
2. Variceal hemorrhage
3. Hepatic encephalopathy
4. Spontaneous bacterial peritonitis (SBP)
5. Hepatorenal syndrome (HRS)
6. Jaundice (severe or progressive)

The 5-year survival for decompensated cirrhosis is 50–70%, and patients who survive a first decompensation event have a substantially higher risk of repeat decompensation and death within 1–2 years.

Clinical Features of Cirrhosis

Physical examination findings in cirrhosis reflect both hepatic dysfunction and portal hypertension:

| Sign | Mechanism | |---|---| | Jaundice / scleral icterus | Impaired bilirubin conjugation and excretion | | Spider angiomata | Elevated circulating estrogens; vasodilation | | Palmar erythema | Peripheral vasodilation; altered sex hormone metabolism | | Gynecomastia / testicular atrophy (men) | Altered sex steroid metabolism | | Caput medusae | Portosystemic collateral circulation around umbilicus | | Splenomegaly | Portal hypertension and congestive splenomegaly | | Ascites | Portal hypertension + hypoalbuminemia | | Asterixis ("flapping tremor") | Hepatic encephalopathy; impaired ammonia clearance | | Dupuytren's contracture | Associated with alcoholic liver disease | | Leukonychia (white nails) / Terry's nails | Hypoalbuminemia | | Peripheral edema | Hypoalbuminemia; secondary hyperaldosteronism |

---

Portal Hypertension and Its Complications

Portal hypertension is defined as an elevation of portal venous pressure, measured as the hepatic venous pressure gradient (HVPG) — the difference between wedged (indirect portal) and free hepatic venous pressure. Normal HVPG is <5 mmHg. Portal hypertension is defined as HVPG ≥5 mmHg; clinically significant portal hypertension is HVPG ≥10 mmHg.

The pathophysiology involves two concurrent processes:

1. Increased intrahepatic vascular resistance: Architectural distortion from fibrous septa and regenerative nodules, plus active vasoconstriction from stellate cell contraction and reduced nitric oxide production
2. Increased portal blood flow: Splanchnic vasodilation (from elevated NO, substance P, and other vasodilators) increases blood flow into the portal system, compounding pressure elevation

Esophageal and Gastric Varices

Portal hypertension leads to the development of portosystemic collateral vessels as the body attempts to decompress the elevated portal pressure. The most clinically dangerous are esophageal varices, which form via the coronary (left gastric) vein — azygos vein pathway.

Key clinical facts:

• Varices develop when HVPG exceeds 10 mmHg; bleeding risk is substantially higher when HVPG >12 mmHg
• Approximately 30–40% of all cirrhotics have esophageal varices at diagnosis; nearly all develop varices by 10 years
• First variceal hemorrhage carries a mortality of 10–20% at 6 weeks, even with optimal endoscopic therapy
• Rebleeding risk within 1 year of first hemorrhage is 60–70% without prophylaxis

Primary prophylaxis (preventing first bleed):

• Non-selective beta-blockers (propranolol, nadolol, carvedilol) reduce HVPG by reducing cardiac output and splanchnic blood flow
• Endoscopic variceal ligation (EVL/banding) for large varices or those intolerant of beta-blockers

Acute variceal hemorrhage management:

• Vasoactive drugs (terlipressin, octreotide, somatostatin) to reduce portal pressure
• IV antibiotics (norfloxacin or ceftriaxone) — reduces bacterial translocation and improves survival
• Urgent endoscopic therapy (banding or sclerotherapy) within 12 hours
• Transjugular intrahepatic portosystemic shunt (TIPS) for refractory bleeding

Secondary prophylaxis (preventing rebleeding): Combination of non-selective beta-blocker + EVL is superior to either alone.

Ascites

Ascites — fluid accumulation in the peritoneal cavity — is the most common complication of cirrhosis, present in approximately 50% of patients with decompensated cirrhosis. The pathophysiology involves:

1. Portal hypertension → splanchnic arterial vasodilation → underfilling of arterial circulation → activation of RAAS, SNS, and ADH → sodium and water retention
2. Hypoalbuminemia → reduced plasma oncotic pressure → fluid leaks into the peritoneal cavity

Diagnostic paracentesis should be performed in all patients with new-onset ascites to confirm the diagnosis and rule out infection and malignancy.

The serum-ascites albumin gradient (SAAG) is the cornerstone diagnostic tool:

| SAAG | Interpretation | |---|---| | ≥1.1 g/dL | High-gradient ascites — portal hypertension is the cause (>97% accuracy) | | <1.1 g/dL | Low-gradient ascites — portal hypertension is NOT the cause (consider malignancy, TB, pancreatic ascites, nephrotic syndrome) |

Treatment:

• Dietary sodium restriction (2 g/day) is the cornerstone of ascites management
• Diuretics: Spironolactone (aldosterone antagonist) + furosemide; ratio 100 mg spironolactone : 40 mg furosemide maintains normal electrolytes
• Large-volume paracentesis (LVP): For tense or refractory ascites; remove >5L with concomitant albumin infusion (8 g per liter removed) to prevent paracentesis-induced circulatory dysfunction (PICD)
• Transjugular intrahepatic portosystemic shunt (TIPS): Reduces portal pressure mechanically; effective for refractory ascites but may precipitate hepatic encephalopathy; improves survival in select patients
• Liver transplantation: Definitive treatment

Spontaneous Bacterial Peritonitis (SBP)

SBP is infection of ascitic fluid without an intra-abdominal surgical source. It occurs when gut bacteria (predominantly gram-negative bacilli — E. coli, Klebsiella) translocate across the intestinal wall into mesenteric lymph nodes and then the peritoneal fluid.

Diagnosis: Ascitic fluid PMN count ≥250 cells/mm³ (or positive culture). Immediate empiric antibiotics (cefotaxime or ceftriaxone) should be started without waiting for culture results, as SBP carries a mortality of 10–30% in hospitalized patients. IV albumin (1.5 g/kg at diagnosis, 1 g/kg at day 3) reduces the incidence of HRS and improves survival.

Long-term secondary prophylaxis with norfloxacin or trimethoprim-sulfamethoxazole significantly reduces SBP recurrence.

Hepatorenal Syndrome (HRS)

Hepatorenal syndrome is a form of acute kidney injury (AKI) occurring in patients with advanced cirrhosis, characterized by severe splanchnic vasodilation leading to renal vasoconstriction and markedly reduced renal perfusion. It occurs in the absence of intrinsic renal pathology — the kidneys are structurally normal but functionally fail due to hemodynamic derangement.

HRS-AKI (formerly Type 1 HRS): Rapid progression (creatinine more than doubles to >2.5 mg/dL within 2 weeks); often precipitated by SBP, large-volume paracentesis without albumin, or GI bleeding; median survival without treatment of days to weeks

HRS-CKD (formerly Type 2 HRS): Gradual, steady decline in renal function; often associated with refractory ascites; median survival of 3–6 months

Diagnosis requires (per ICA-AKI criteria 2015):

• Cirrhosis with ascites
• Rise in serum creatinine ≥0.3 mg/dL within 48 hours or ≥50% rise from baseline within 7 days
• No response to 2 days of diuretic withdrawal and albumin (1 g/kg/day for 2 days)
• Absence of shock, nephrotoxic drugs, or parenchymal renal disease (normal urinalysis)

Treatment:

• Vasoconstrictors: Terlipressin (preferred, reduces mortality) + albumin; norepinephrine in ICU settings; midodrine + octreotide (less effective, used where terlipressin unavailable)
• Mean arterial pressure (MAP) monitoring is essential — target MAP ≥75 mmHg during vasoconstrictor therapy. Use the MAP Calculator to track this parameter.
• TIPS: May reverse HRS-CKD in selected patients
• Renal replacement therapy (RRT): Bridge to transplant only, as HRS is not primarily a renal disease

Hepatic Encephalopathy (HE)

Hepatic encephalopathy is a neuropsychiatric complication of advanced liver disease caused by the failure to adequately clear nitrogenous waste products — principally ammonia — from portal blood. Ammonia, produced by gut bacteria and amino acid catabolism, normally undergoes hepatic conversion to urea. In cirrhosis, ammonia bypasses the damaged liver via portosystemic shunts and crosses the blood-brain barrier, causing astrocyte swelling, cerebral dysfunction, and neurological manifestations.

Grading (West Haven Criteria):

| Grade | Clinical Features | |---|---| | Grade I | Mild confusion, sleep disturbance, shortened attention span, asterixis may be present | | Grade II | Lethargy, obvious personality change, disorientation, asterixis present | | Grade III | Somnolent but arousable, marked confusion, bizarre behavior, asterixis | | Grade IV | Coma — unresponsive to painful stimuli |

Precipitants (must be actively sought and corrected):

• Gastrointestinal bleeding (massive protein load)
• Infection / SBP
• Dehydration or over-diuresis (increases azotemia)
• Constipation
• Electrolyte abnormalities (hyponatremia, hypokalemia)
• Sedating medications (benzodiazepines, opioids)
• Dietary protein overload
• Hepatic vein thrombosis or TIPS-related shunting

Treatment:

• Lactulose: Acidifies the colon, traps ammonia as ammonium (NH4+), promotes bowel evacuation; titrate to 2–3 soft bowel movements per day; first-line therapy
• Rifaximin: Non-absorbable antibiotic that reduces gut ammonia-producing bacteria; added to lactulose for secondary prophylaxis (RFHE trial showed 58% reduction in HE episodes)
• Zinc supplementation: Zinc is a cofactor for urea cycle enzymes; often deficient in cirrhosis; supplementation may improve subclinical HE
• Protein restriction: Once recommended but now discouraged — protein restriction worsens malnutrition and sarcopenia, which actually worsens HE; current guidelines recommend adequate protein intake (1.2–1.5 g/kg/day)

---

Child-Pugh Score

The Child-Pugh score (originally developed by Child and Turcotte in 1964, modified by Pugh in 1973) was the first validated scoring system for assessing liver disease severity and surgical risk in cirrhotic patients. Despite its age, it remains widely used clinically, incorporated into guidelines, and required by many drug dosing algorithms.

Child-Pugh Variables and Scoring

| Variable | 1 Point | 2 Points | 3 Points | |---|---|---|---| | Total bilirubin (mg/dL) | <2 | 2–3 | >3 | | Albumin (g/dL) | >3.5 | 2.8–3.5 | <2.8 | | INR (Prothrombin time) | <1.7 | 1.7–2.3 | >2.3 | | Ascites | None | Mild (controlled with diuretics) | Moderate-severe (refractory) | | Hepatic encephalopathy | None | Grade I–II (or controlled) | Grade III–IV (or refractory) |

Total score ranges from 5 to 15.

Child-Pugh Classification

| Class | Total Score | 1-Year Survival | 2-Year Survival | Surgical Mortality | |---|---|---|---|---| | Class A | 5–6 | ~100% | ~85% | 10% | | Class B | 7–9 | ~80% | ~60% | 30% | | Class C | 10–15 | ~45% | ~35% | 82% |

Clinical Applications of Child-Pugh

• Surgical risk stratification: Child-Pugh C patients have prohibitively high surgical mortality and should not undergo elective abdominal surgery
• Drug dosing: Many hepatically metabolized drugs have dosing adjustments based on Child-Pugh class (e.g., Child-Pugh C contraindications for certain chemotherapy agents, anticoagulants, and antifungals)
• Prognosis communication: Widely understood by surgeons, anesthesiologists, and non-hepatologist physicians
• Screening for transplant listing: Child-Pugh C traditionally triggered transplant evaluation

Use the Child-Pugh Calculator on this site to calculate your score and class.

Limitations of Child-Pugh

The Child-Pugh score has important limitations that led to the development of MELD:

1. Subjectivity: "Ascites" and "hepatic encephalopathy" are subjectively graded, leading to inter-rater variability
2. Ceiling effect: Scores of 14–15 cluster many patients at the top without further discrimination of short-term mortality risk
3. No renal function: Does not incorporate creatinine or renal function, which strongly predicts mortality in cirrhotic patients
4. Not validated for transplant allocation: UNOS transitioned from Child-Pugh to MELD in 2002 because MELD better predicted 3-month waitlist mortality

---

MELD Score

The Model for End-Stage Liver Disease (MELD) was originally developed by Kamath et al. at the Mayo Clinic in 2001 to predict 3-month mortality after TIPS procedure, and was subsequently validated as a predictor of 90-day waitlist mortality in patients with end-stage liver disease. The United Network for Organ Sharing (UNOS) adopted MELD for liver transplant organ allocation in February 2002, replacing the Child-Pugh-based system.

Original MELD Formula (MELD-Na, pre-2022)

MELD = 3.78 × ln(bilirubin mg/dL) + 11.2 × ln(INR) + 9.57 × ln(creatinine mg/dL) + 6.43

The MELD-Na version, which adds serum sodium, became the standard for UNOS allocation in 2016:

MELD-Na = MELD + 1.32 × (137 − Na) − [0.033 × MELD × (137 − Na)]

Where Na is capped between 125–137 mEq/L and creatinine is capped at 4.0 mg/dL.

MELD 3.0 (2022 Update)

In 2022, Kim et al. published the MELD 3.0 update, which was adopted by UNOS/OPTN in 2022 to address a major equity gap: the original MELD equation systematically underestimated mortality in women compared to men, resulting in women dying on the waitlist at higher rates. MELD 3.0 incorporates:

• Female sex (adds 1.33 points)
• Serum albumin (replaces creatinine cap)
• Creatinine
• Bilirubin
• INR
• Sodium

MELD 3.0 improved waitlist mortality prediction in women by approximately 10% and closed the sex gap in transplant access. This is now the standard formula used by UNOS/OPTN for all US liver transplant allocation.

MELD Score Interpretation

| MELD Score | Approximate 90-Day Mortality Without Transplant | Clinical Significance | |---|---|---| | <10 | <5% | Low urgency; monitor closely | | 10–15 | 5–10% | Consider listing evaluation | | >15 | >15% | Threshold for active transplant listing | | 20–24 | ~25–30% | Moderate urgency; active on waitlist | | 25–29 | ~40–45% | High urgency; significant waitlist mortality | | 30–34 | ~50–55% | Very high urgency | | ≥35 | >70% | Status 1A exception consideration |

Transplant listing thresholds:

• Most centers list patients when MELD >15 (benefit of transplantation outweighs risk)
• MELD >25: High priority for organ allocation
• Status 1A: Acute liver failure or MELD >40 or specific exception criteria

Use the MELD Score Calculator on this site to calculate and interpret your score.

MELD Score Limitations

• Does not capture hepatic encephalopathy (which profoundly impairs quality of life but not always MELD)
• Does not account for muscle wasting/sarcopenia (a major independent predictor of waitlist mortality)
• Renal function component can be misleading (hemodialysis caps creatinine at 4.0 mg/dL, which may over-estimate hepatic contribution to mortality)
• MELD exceptions exist for HCC, hepatopulmonary syndrome, and portopulmonary hypertension, where the calculated score may not reflect true disease severity

---

Liver Transplantation

Liver transplantation is the definitive treatment for end-stage liver disease and acute liver failure that cannot be managed with medical therapy. The 5-year post-transplant survival is approximately 70–80%, with leading transplant centers achieving even better outcomes.

UNOS/OPTN Allocation System

The US liver transplant allocation system, managed by UNOS/OPTN, prioritizes by:

1. Status 1A (highest priority): Acute liver failure (fulminant hepatic failure) with life expectancy <7 days without transplant; primary non-function of a prior transplant within 7 days; hepatic artery thrombosis within 7 days of transplant
2. Status 1B: Pediatric patients with chronic liver disease and MELD/PELD ≥25
3. MELD/PELD score: All adult patients ranked by MELD 3.0 within blood type and geographic zone — higher score = higher priority

Listing Criteria for Transplant Evaluation

Referral for transplant evaluation is appropriate when:

• MELD score ≥15 (survival benefit of transplant exceeds operative risk)
• Child-Pugh C cirrhosis
• First decompensation event (ascites, variceal hemorrhage, HE, SBP, HRS)
• Acute liver failure
• Hepatocellular carcinoma within Milan criteria (see below)

Contraindications to Liver Transplant

Absolute contraindications:

• Extrahepatic malignancy without sufficient disease-free interval
• Uncontrolled severe cardiopulmonary disease (e.g., ejection fraction <40%, severe pulmonary hypertension with mean PAP >50 mmHg)
• Active substance abuse (alcohol or illicit drugs — most centers require 6 months abstinence)
• Uncontrolled serious infection or sepsis
• Anatomic abnormalities that preclude transplant

Relative contraindications (center-dependent):

• Age >70 years (not an absolute barrier at experienced centers)
• HIV (now well-controlled HIV is not a contraindication; excellent outcomes reported)
• Obesity with BMI >40 kg/m² (increased perioperative risk)
• Morbid psychiatric illness or limited social support

Milan Criteria for Hepatocellular Carcinoma

The Milan criteria (Mazzaferro et al., NEJM 1996) define the HCC staging within which liver transplantation is justified:

• Single tumor ≤5 cm in diameter, OR
• Up to 3 tumors, each ≤3 cm, with no macrovascular invasion and no extrahepatic spread

Patients meeting Milan criteria have post-transplant 5-year survival of 70–75% with recurrence rates <15%. Patients within Milan criteria receive MELD exception points to account for the risk of tumor progression while on the waitlist.

Living Donor Liver Transplantation (LDLT)

Living donor transplantation involves surgical resection of a portion of the liver (typically the right lobe, comprising ~60% of liver volume) from a healthy volunteer (usually a first-degree relative). The donor remnant and recipient graft both regenerate within 6–8 weeks. LDLT accounts for approximately 6–8% of adult liver transplants in the US and up to 90% in countries with few deceased donors (Japan, South Korea).

---

Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma is the most common primary liver cancer and one of the few malignancies with rising incidence in developed countries, largely driven by NAFLD/MASH and the aging population of HCV-infected individuals. HCC is the third leading cause of cancer death worldwide, killing approximately 700,000 people annually.

Risk Factors for HCC

• Cirrhosis from any cause: Annual HCC incidence 1–8% in cirrhotic patients (highest in HBV and HCV)
• Hepatitis B: HBV can cause HCC even without cirrhosis (uniquely among common liver diseases); constitutes 50–55% of global HCC burden
• Hepatitis C: Risk primarily mediated through cirrhosis; risk persists even after SVR in cirrhotic patients
• NAFLD/MASH cirrhosis: Growing contributor to HCC, especially in metabolic syndrome patients
• Alcoholic cirrhosis
• Aflatoxin B1 exposure (a fungal toxin contaminating food crops in sub-Saharan Africa and Southeast Asia)
• Hereditary hemochromatosis

HCC Surveillance

The AASLD, EASL, and APASL all recommend HCC surveillance in patients with cirrhosis and in certain HBV patients without cirrhosis:

• Surveillance tool: Liver ultrasound with or without alpha-fetoprotein (AFP) every 6 months
• AFP >20 ng/mL in a cirrhotic patient warrants further imaging; AFP >400 ng/mL is diagnostic in the right context
• Suspicious ultrasound findings should be followed by contrast-enhanced CT or MRI (the gold standard for HCC diagnosis — biopsy is often not required when imaging is classic)

Barcelona Clinic Liver Cancer (BCLC) Staging

The BCLC staging system links tumor stage, liver function (Child-Pugh), and performance status to treatment recommendations:

| BCLC Stage | Description | Treatment | |---|---|---| | 0 (Very early) | Single tumor <2 cm, Child-Pugh A, PS 0 | Ablation or resection | | A (Early) | Single or ≤3 nodules ≤3 cm, Child-Pugh A–B, PS 0 | Resection, ablation, or transplant | | B (Intermediate) | Large multifocal, no vascular invasion, PS 0 | Transarterial chemoembolization (TACE) | | C (Advanced) | Vascular invasion or extrahepatic spread, PS 1–2 | Systemic therapy (atezolizumab + bevacizumab, sorafenib) | | D (Terminal) | End-stage liver function, PS 3–4 | Best supportive care |

---

Frequently Asked Questions

Can cirrhosis be reversed?

Early fibrosis (F1–F2) can be substantially reversed with effective treatment of the underlying cause — HCV cure, alcohol abstinence, weight loss in NAFLD. Even some patients with advanced fibrosis (F3) experience significant regression. Established cirrhosis (F4) was long considered irreversible, but emerging evidence shows partial regression is possible in patients who achieve sustained remission of the causative disease. Complete normalization of hepatic architecture is generally not achievable once cirrhosis is established, and patients remain at risk for HCC and portal hypertension complications even after fibrosis regression.

What MELD score qualifies for liver transplant listing?

Most transplant centers consider listing patients for liver transplantation when MELD ≥15, which is the threshold at which the survival benefit of transplant exceeds the perioperative mortality risk. Some centers use additional clinical criteria (first decompensation event, refractory ascites, recurrent HE) to list patients with MELD below 15. MELD >25 indicates high urgency, and MELD ≥35 typically places patients near the top of regional waiting lists.

Can fatty liver (NAFLD) turn into cirrhosis?

Yes. Simple hepatic steatosis has a low progression risk (<5% over 15 years), but NASH — characterized by inflammation and ballooning degeneration on top of fat — carries a 15–25% risk of cirrhosis over 10–20 years. The primary determinants of progression are the degree of fibrosis at baseline, presence of diabetes and obesity, and ongoing metabolic stressors. Weight loss of 7–10% of body weight (sustained) can reverse NASH histologically, including early fibrosis.

What is a normal APRI score?

An APRI score <0.5 is generally considered reassuring — it has a high negative predictive value for significant fibrosis (≥F2) in HCV-related liver disease. Scores between 0.5 and 1.5 are indeterminate and require further assessment with FIB-4, elastography, or liver biopsy. Scores >1.5 have high specificity for significant fibrosis. Note that APRI cutoffs may differ slightly by underlying liver disease etiology.

How is ascites treated in cirrhosis?

First-line treatment is dietary sodium restriction (2 g/day) combined with oral diuretics — spironolactone and furosemide at a 100:40 mg ratio. Diuretics are titrated every 3–5 days to achieve 0.5–1 kg/day weight loss (up to 1 kg/day if edema is present). Patients with tense or refractory ascites require large-volume paracentesis (>5L removed) with concomitant albumin infusion (8 g per liter removed). Diuretic-refractory ascites may require TIPS or listing for liver transplantation. IV albumin infusions are increasingly used in outpatient settings for cirrhosis management based on the PILOT and ATTIRE trials.

What is the difference between Child-Pugh and MELD scores?

Both assess liver disease severity, but with different purposes and compositions. Child-Pugh uses five variables (bilirubin, albumin, INR, ascites, encephalopathy) and classifies patients into Class A, B, or C — useful for surgical risk stratification and drug dosing. MELD uses a continuous mathematical formula (bilirubin, INR, creatinine, and sodium in MELD-Na; plus sex and albumin in MELD 3.0) and predicts 90-day mortality more precisely. MELD is the standard for US liver transplant organ allocation because it objectively ranks patients by mortality risk without subjective components.

What foods should I avoid with cirrhosis?

Patients with cirrhosis should: (1) restrict dietary sodium to 2 g/day to manage or prevent ascites; (2) avoid alcohol completely (even small amounts accelerate fibrosis in compensated cirrhosis and precipitate decompensation); (3) avoid raw shellfish and undercooked seafood (risk of Vibrio vulnificus septicemia, which is rapidly fatal in cirrhotics); (4) limit high-glycemic carbohydrates (many cirrhotics have hepatogenous diabetes); (5) avoid NSAIDs (reduce renal prostaglandins, precipitate HRS). Protein restriction is NOT recommended — adequate protein intake (1.2–1.5 g/kg/day, ideally distributed across 4–6 meals with a late-night snack) reduces sarcopenia and actually improves hepatic encephalopathy outcomes.

What are the warning signs that cirrhosis is worsening?

Urgent medical evaluation is warranted for: new or rapidly worsening abdominal swelling (ascites), confusion or personality change (hepatic encephalopathy), vomiting blood or black tarry stools (variceal hemorrhage), fever and abdominal pain (spontaneous bacterial peritonitis), marked jaundice or dark urine, leg swelling, or a decrease in urine output (hepatorenal syndrome). Any decompensation event substantially worsens prognosis and should trigger re-evaluation for liver transplantation.

---

Summary

Liver disease progresses silently until it cannot. Understanding its causes — NAFLD/MASH, alcohol, viral hepatitis, autoimmune and genetic conditions — enables earlier detection and intervention. Non-invasive fibrosis testing with FIB-4 and APRI can identify patients at risk for advanced fibrosis before symptoms develop. Once cirrhosis establishes, the Child-Pugh and MELD scoring systems provide validated, guideline-endorsed frameworks for prognosis, transplant listing, and perioperative risk assessment.

The most important principle in managing cirrhosis is treating the underlying cause — because fibrosis regression, while incomplete in established cirrhosis, significantly improves outcomes, reduces decompensation risk, and can even reduce HCC incidence. The second most important principle is vigilance for complications: surveillance endoscopy for varices, 6-monthly HCC ultrasound, monitoring of renal function and sodium, and aggressive management of any decompensation event.

Liver transplantation remains the only cure for decompensated end-stage liver disease, and early hepatology referral for transplant evaluation is one of the most important steps a clinician can take for an eligible cirrhotic patient.

---

Sources

• AASLD Practice Guidance on Nonalcoholic Fatty Liver Disease (MASLD/MASH) | Hepatology 2023
• EASL Clinical Practice Guidelines on Non-Invasive Tests for Evaluation of Liver Disease Severity and Prognosis 2021 | Journal of Hepatology
• Baveno VII Consensus on Portal Hypertension 2022 | Journal of Hepatology
• Kamath PS et al. A model to predict survival in patients with end-stage liver disease | Hepatology 2001
• Kim WR et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the 21st Century | Hepatology 2021
• Pugh RN et al. Transection of the oesophagus for bleeding oesophageal varices | British Journal of Surgery 1973
• EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis | Journal of Hepatology 2018
• AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
• WHO Global Hepatitis Report 2024
• Mazzaferro V et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis | NEJM 1996
• Villanueva C et al. Acute-on-Chronic Liver Failure: Pathophysiology, Diagnosis, and Management | NEJM 2023

---

Disclaimer: This guide is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Liver disease should be evaluated and managed by a qualified gastroenterologist or hepatologist. Patients with known or suspected cirrhosis should work with their healthcare team for individualized management, including regular screening for complications and assessment for liver transplantation when appropriate.